drugset / Trial / NCT00387192
A Study With OPTIVATE® in People With Von Willebrand Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and safety of OPTIVATE® in long-term use over at least 12 months.
Timeline
- Start
- 2006-11
- Primary completion
- —
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Wilate | Protein / enzyme biologic | 80 iu/kg | — |